Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2005-10-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00245024

Locations: 🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis
Other: pharmacogenomic studies

First Posted Date: 2005-10-27

Last Posted Date: 2014-10-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00245063

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

Phase 1

Completed

Conditions: Advanced Malignant Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Sorafenib Tosylate
Drug: Tipifarnib

First Posted Date: 2005-10-27

Last Posted Date: 2017-04-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00244972

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking

Not Applicable

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2005-10-27

Last Posted Date: 2015-05-01

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00245076

Locations: 🇺🇸
Tobacco Control Research Branch, Rockville, Maryland, United States

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Phase 2

Completed

Conditions: Ciliary Body and Choroid Melanoma, Small Size
Extraocular Extension Melanoma
Stage IV Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Acral Lentiginous Malignant Melanoma
Intraocular Melanoma
Iris Melanoma
Lentigo Maligna Malignant Melanoma
Recurrent Melanoma
Stage, Intraocular Melanoma

Interventions: Drug: cediranib maleate

First Posted Date: 2005-10-21

Last Posted Date: 2018-08-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00243061

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: vorinostat
Drug: gemcitabine hydrochloride

First Posted Date: 2005-10-21

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00243100

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: bortezomib
Drug: tipifarnib
Other: laboratory biomarker analysis

First Posted Date: 2005-10-21

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT00243035

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Advanced Malignant Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatous Mesothelioma
Epithelial Mesothelioma

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2005-10-21

Last Posted Date: 2018-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00243074

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Recruiting

Conditions: Esophageal Cancers NOS
Lung Cancer NOS
Malignant Pleural Mesotheliomas NOS
Thoracic Cancers
Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura

First Posted Date: 2005-10-20

Last Posted Date: 2025-06-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1310

Registration Number: NCT00242723

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: vorinostat
Procedure: conventional surgery

First Posted Date: 2005-10-13

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 103

Registration Number: NCT00238303

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy